Scholars Central

Mini reviewPublished 2017

Colon Cancer and Immunotherapy: CD40 Ligand as a Potential Therapeutic Target

Authors: Orfanos S, Patelis N, Davakis S, Vailas M, Damaskos C, Margonis GA, Pikoulis E, Antoniou E

Molecular and Genetic Medicine

Volume 11 · Issue 1 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

CD40, a member of the tumor necrosis factor (TNF) superfamily, it is broadly expressed on a variety of cells. There are studies to suggest that the expression of CD40 is correlated to several malignancies, while its innate therapeutic qualities are yet to be confirmed. Colon cancer is one of the most common cancers, while little can be done for the patients with advance colon cancer even at the presence time. CD40 are present in the colon cancer, and are a possible therapeutic immunotherapy target in order to enhance the overall survival rates of the patients with advanced disease.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalMolecular and Genetic Medicine
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Orfanos S”
  • BylineArticles whose byline prints “Patelis N”
  • BylineArticles whose byline prints “Davakis S”
  • BylineArticles whose byline prints “Vailas M”
  • BylineArticles whose byline prints “Damaskos C”
  • BylineArticles whose byline prints “Margonis GA”
  • BylineArticles whose byline prints “Pikoulis E”
  • BylineArticles whose byline prints “Antoniou E”